Shawn M. Ferguson
Vanderbilt University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shawn M. Ferguson.
The Journal of Comparative Neurology | 2003
Laura Kus; Ewa D Borys; Ya Ping Chu; Shawn M. Ferguson; Randy D. Blakely; Marina E. Emborg; Jeffrey H. Kordower; Allan I. Levey; Elliott J. Mufson
A mouse monoclonal antibody (clone 62‐2E8) raised against a human recombinant high‐affinity choline transporter (CHT)‐glutathione‐S‐transferase fusion protein was used to determine the distribution of immunoreactive profiles containing this protein in the monkey central nervous system (CNS). Within the monkey telencephalon, CHT‐immunoreactive perikarya were found in the striatum, nucleus accumbens, medial septum, vertical and horizontal limb nuclei of the diagonal band, nucleus basalis complex, and the bed nucleus of the stria terminalis. Dense fiber staining was observed within the islands of Calleja, olfactory tubercle, hippocampal complex, amygdala; moderate to light fiber staining was seen in iso‐ and limbic cortices. CHT‐containing fibers were also present in sensory and limbic thalamic nuclei, preoptic and hypothalamic areas, and the floccular lobe of the cerebellum. In the brainstem, CHT‐immunoreactive profiles were observed in the pedunculopontine and dorsolateral tegmental nuclei, the Edinger‐Westphal, oculomotor, trochlear, trigeminal, abducens, facial, ambiguus, dorsal vagal motor, and hypoglossal nuclei. In the spinal cord, CHT‐immunoreactive ventral horn motoneurons were seen in close apposition to intensely immunoreactive C‐terminals at the level of the cervical spinal cord. CHT immunostaining revealed a similar distribution of labeled profiles in the aged human brain and spinal cord. Dual fluorescent confocal microscopy revealed that the majority of CHT immunoreactive neurons contained the specific cholinergic marker, choline acetyltransferase, at all levels of the monkey CNS. The present observations indicate that the present CHT antibody labels cholinergic structures within the primate CNS and provides an additional marker for the investigation of cholinergic neuronal function in aging and disease. J. Comp. Neurol. 463:341–357, 2003.
Neuroscience | 2010
David Lund; Alicia M. Ruggiero; Shawn M. Ferguson; Jane Wright; Brett A. English; Peter A. Reisz; Sarah M. Whitaker; Amanda C. Peltier; Randy D. Blakely
The presynaptic, hemicholinium-3 sensitive, high-affinity choline transporter (CHT) supplies choline for acetylcholine (ACh) synthesis. In mice, a homozygous deletion of CHT (CHT-/-) leads to premature cessation of spontaneous or evoked neuromuscular signaling and is associated with perinatal cyanosis and lethality within 1 h. Heterozygous (CHT+/-) mice exhibit diminished brain ACh levels and demonstrate an inability to sustain vigorous motor activity. We sought to explore the contribution of CHT gene dosage to motor function in greater detail using transgenic mice where CHT is expressed under control of the motor neuron promoter Hb9 (Hb9:CHT). On a CHT-/- background, the Hb9:CHT transgene conferred mice with the ability to move and breath for a postnatal period of ∼24 h, thus increasing survival. Conversely, Hb9:CHT expression on a wild-type background (CHT+/+;Hb9:CHT) leads to an increased capacity for treadmill running compared to wild-type littermates. Analysis of the stimulated compound muscle action potential (CMAP) in these animals under basal conditions established that CHT+/+;Hb9:CHT mice display an unexpected, bidirectional change, producing either elevated or reduced CMAP amplitude, relative to CHT+/+ animals. To examine whether these two groups arise from underlying changes in synaptic properties, we used high-frequency stimulation of motor axons to assess CMAP recovery kinetics. Although CHT+/+; Hb9:CHT mice in the two groups display an equivalent, time-dependent reduction in CMAP amplitude, animals with a higher basal CMAP amplitude demonstrate a significantly enhanced rate of recovery. To explain our findings, we propose a model whereby CHT support for neuromuscular signaling involves contributions to ACh synthesis as well as cholinergic synaptic vesicle availability.
The Journal of Neuroscience | 2003
Shawn M. Ferguson; Valentina Savchenko; Subbu Apparsundaram; Melissa Zwick; Jane Wright; Craig J. Heilman; Hong Yi; Allan I. Levey; Randy D. Blakely
Biochemical and Biophysical Research Communications | 2000
Subbu Apparsundaram; Shawn M. Ferguson; Alfred L. George; Randy D. Blakely
Molecular Interventions | 2004
Shawn M. Ferguson; Randy D. Blakely
Cardiovascular Research | 2004
Donald B. Hoover; Charles E. Ganote; Shawn M. Ferguson; Randy D. Blakely; Rodney L. Parsons
Biochemical Society Transactions | 2001
Subramaniam Apparsundaram; Shawn M. Ferguson; Randy D. Blakely
Molecular Pharmacology | 2003
Laura A. Volpicelli-Daley; Anna Hrabovska; Ellen G. Duysen; Shawn M. Ferguson; Randy D. Blakely; Oksana Lockridge; Allan I. Levey
Archive | 2001
Randy D. Blakely; Subramaniam Apparsundaram; Shawn M. Ferguson
Archive | 2003
Randy D. Blakely; Subramaniam Apparsundaram; Shawn M. Ferguson